GoodRx Holdings (GDRX) Equity Average (2019 - 2026)

GoodRx Holdings' Equity Average history runs 8 years deep, the most recent figure standing at $619.1 million for Q1 2026.

• In Q1 2026, Equity Average fell 10.21% year-over-year to $619.1 million; the TTM figure through Mar 2026 stood at $619.1 million (down 10.21% YoY), while the FY2025 annual figure was $670.5 million, down 9.8% from the prior year.
• Equity Average came in at $619.1 million for Q1 2026 at GoodRx Holdings, up from $608.5 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $888.3 million in Q3 2023 to a low of $608.5 million in Q4 2025.
• A 5-year average of $737.4 million and a median of $710.5 million in 2024 frame the typical range for Equity Average.
• Across the five-year window, Equity Average gained 10.8% in 2022 and dropped 24.52% in 2024, its largest moves.
• GoodRx Holdings' Equity Average stood at $801.6 million in 2022, then rose by 2.5% to $821.6 million in 2023, then decreased by 13.52% to $710.5 million in 2024, then fell by 14.36% to $608.5 million in 2025, then climbed by 1.75% to $619.1 million in 2026.
• According to Business Quant data, Equity Average over the past three periods registered $619.1 million, $608.5 million, and $621.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison